Early Start's new website

Head to http://www.cnn.com/shows/early-start for your news.

 

 

 

May 16th, 2013
10:39 AM ET

Breakthrough in understanding Stem Cells: CNN's Senior Medical Correspondent Elizabeth Cohen Reports

 CNN's Senior Medical Correspondent explains new research that could impact our understanding of stem cells. This breakthrough is noteworthy because based on this research these stem cells would be 'genetically identical to you,' says Cohen. This is very important because this way your body will not reject the stem cells.

This new research would allow for samples of an individual’s skin cells to be retrieved, and then turned into an embryo. From this point these embryos would then be made into stem cells.  At this point researches are only at the stage where they have taken cells and turned them into embryotic stem cells. However, looking into the future these replicated stem cells could be used to create cardiac muscle, nerve cells or bone marrow cells.

These replicated stem cells could be used to help patients with diabetes, Parkinson’s disease, and even Leukemia.

Researchers estimate it could be another five-ten years before this research is complete. 

READ MORE: Scientists report first success in cloning human stem cells


Filed under: Health
soundoff (One Response)
  1. Bill

    The reporter stated that she has been waiting for years for this stem cell breakthrough, yet she failed to mention the ethical issues regarding the source of the cells, i.e., cloned human embryos. Both anchors expressed their excitement, too, without one word about the ethical issues. Some objectivity would have been nice. NPR provided both sides of the issue in its report; I'm disappointed that CNN couldn't do the same.

    May 16, 2013 at 10:01 pm | Reply

Post a comment


 

CNN welcomes a lively and courteous discussion as long as you follow the Rules of Conduct set forth in our Terms of Service. Comments are not pre-screened before they post. You agree that anything you post may be used, along with your name and profile picture, in accordance with our Privacy Policy and the license you have granted pursuant to our Terms of Service.